shAPLN ameliorates histologic severity of OA. (A) Micro-CT images of the control knee, anterior cruciate transection (ACLT) knee, and shAPLN-transfected ACLT knee (n = 8). (B–E) OARSI scores (B), micro-CT parameters, including trabecular separation (C), trabecular thickness (D), and volumetric bone mineral density (E), of the control knee, ACLT knee, and shAPLN-transfected ACLT knee. (F) Specimens from the control knee, ACLT knee, and shAPLN-transfected ACLT knee were immunostained with Safranin-O, VEGF, CD31, CD133, and CD34. * p < 0.05 compared with control; # p < 0.05 compared with the APLN-treated group.